Susanna Naggie
Infectious Disease · Durham, NCNPI 1831248855
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,540 of the $4,118 with a category attached, or 61.7%. Gilead accounts for 63.6% of it on its own, with 1 other manufacturer making up the rest. 2021 is the largest year on record at $2,540, more than ten times the $78 reported in 2019.
Across 4 payments — averaging $1029.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Theratechnologies Inc.$2K
Across 34 payments — averaging $79,487 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2.3M
- GSK$200K
- Gilead$195K
- E.r. Squibb & Sons, L.L.C.$53K
- Apotex Inc.$2K
What the payments were for
- Consulting fees$2,54062%
- Speaking & faculty fees$1,50036%
- Food & beverage$782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $2,618 |
| Theratechnologies Inc. | 1 | $1,500 |
How this compares
$4,118 in reported general payments places this provider in the 80th percentile of 250 infectious disease providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 39 | $162,079 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 19 | $68,328 |
| IsentressRaltegravir Potassium | 12 | $25,771 |
| TivicayDolutegravir Sodium | 11 | $22,945 |
| Metoprolol Succinate | 11 | $256 |
| Atorvastatin Calcium | 32 | $250 |
| Tamsulosin Hcl | 11 | $226 |
| Furosemide | 11 | $69 |
| Amlodipine Besylate | 26 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $2,618 | $162,07939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 250 infectious disease providers in North Carolina.
Other infectious disease in Durham
- Cristina GasparettoDurham$613K
- Cameron WolfeDurham$112K
- Gordon CoreyDurham$46K
- Mitchell HorwitzDurham$45K
- Vance FowlerDurham$43K
- Sonali AdvaniDurham$37K
- Christopher WoodsDurham$16K
- Steve TaylorDurham$8K
- Barbara AlexanderDurham$6K
- John PerfectDurham$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.